Comparison of Effects on Different Doses of Sacubitril Valsartan in the Treatment of Dilated Cardiomyopathy with Heart Failure
Objective:To compare the effects of different doses of sacubitril valsartan in the adjuvant treatment of patients with dilated cardiomyopathy(DCM)and heart failure.Methods:According to the random number table method,92 patients with DCM heart failure who were treated in our hospital from August 2019 to September 2022 were divided into low-dose group(46 cases)and high-dose group(46 cases).Two groups of patients were given different initial doses of sacubitril valsartan tablets.The initial dose of the low-dose group was 50 mg,and the initial dose of the high-dose group was 100 mg.The myocardial serological indexes,echocardiographic indexes and related adverse reactions were compared between the two groups.Results:After one month of treatment,the levels of D-dimer,hs-cTnT and NT-proBNP in the two groups were lower than those before treatment(P<0.05),but there was no significant difference between the low-dose group and the high-dose group(P>0.05).The levels of LVEF,CVP and PAWP in the two groups were higher than those before treatment,and the level of LVESD in the two groups was lower than that before treatment(P<0.05).However,there was no significant difference between the low-dose group and the high-dose group(P>0.05).The total incidence of adverse reactions in the high-dose group was 21.74%,which was higher than 6.52%in the low-dose group(P<0.05).Conclusion:The effect of sacubitril valsartan with 50 mg/time as the initial dose(low dose)as the adjuvant therapy is equivalent to that of high dose,which can effectively improve the cardiac function of patients,inhibit the impact of ventricular remodeling,and has a low incidence of adverse reactions and good safety.
NETL
NSTL
万方数据
